McCoy D, Wong E, Kuyumjian A G, Wynd M A, Sebti R, Munk G B
Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Hackensack, New Jersey, USA.
Transpl Infect Dis. 2011 Apr;13(2):117-21. doi: 10.1111/j.1399-3062.2010.00561.x. Epub 2010 Aug 29.
A total of 26 adults with hematologic malignancies and/or hematopoietic stem cell transplant were treated for respiratory syncytial virus (RSV) infection based on an institutional guideline. Thirteen patients received aerosolized ribavirin, and 13 received aerosolized ribavirin and intravenous palivizumab. Two deaths, not attributed to RSV infection, occurred within 90 days of diagnosis.
根据一项机构指南，共有26例患有血液系统恶性肿瘤和/或接受造血干细胞移植的成人接受了呼吸道合胞病毒（RSV）感染的治疗。13例患者接受了雾化利巴韦林治疗，13例接受了雾化利巴韦林和静脉注射帕利珠单抗治疗。在诊断后90天内发生了2例死亡，死亡原因并非RSV感染。
